RXRX Recursion Pharmaceuticals

NEUTRAL Impact: 2/10 PRESS-RELEASE
Horizon months Filed May 29, 2026 Processed 14d 18h ago Wire GlobeNewswire
Press release: announcement
Latest settled — T+5d
RXRX ▼ -12.53% at T+5d
NEUTRAL call ✗ call lost -12.53% · α vs SPY -9.78% · entry $3.79 → $3.32
Next anchor: T+20d in 16d
Currently $3.15 · -16.89% from $3.79 entry
Entry anchored
May 29, 04:00 PM ET
via Databento tick
T+1d
-4.75%
call -4.75% · α -4.90%
$3.61
settled 12d ago
T+5d
-12.53%
call -12.53% · α -9.78%
$3.32
settled 8d ago
T+20d
call — · α —
in 16d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

Recursion Pharmaceuticals granted inducement RSU awards covering ~2.99 million shares to 33 new employees under its 2024 Inducement Equity Incentive Plan, as a material inducement to their employment. The awards vest over four years with a one-year cliff. This is a routine equity grant for new hires and does not reflect any change in business operations or financial performance.

Actionable Insight

Routine inducement grants for new hires — no material impact on stock. Monitor for any future insider selling patterns or changes in employee retention, but this filing alone does not warrant trading action.

Key Facts

  • Inducement RSU awards covering 2,991,840 shares granted to 33 new employees.
  • Awards vest 1/4th on first quarterly vesting date after one-year anniversary, then 1/16th quarterly thereafter.
  • Grants made under the 2024 Inducement Equity Incentive Plan per Nasdaq Listing Rule 5635(c)(4).
  • No financial terms or performance metrics disclosed; standard new-hire equity compensation.

Financial Impact

~2.99 million shares granted, representing approximately 0.9% of outstanding shares (based on ~330M shares outstanding per market cap of $1.8B at ~$5.45/share). No cash consideration.

dilution

Risk Factors

  • Potential dilution of ~0.9% over vesting schedule, but immaterial in near term.
  • No performance conditions — awards are time-based, so retention risk if stock declines.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
57% bullish (14 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3303818
9 reports for RXRX
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for RXRX — sortable, filterable
Type Now
Jun 11, 2026
2d ago
Institutional Cluster
NEUTRAL ★ 3/10
$3.10 awaiting T+5awaiting T+5$3.15 (+1.61%)
Jun 5, 2026
7d ago
Insider Cluster
NEUTRAL ★ 2/10
$3.32 awaiting T+5awaiting T+5$3.15 (−4.98%)
May 29, 2026
14d ago
Press Release
NEUTRAL ★ 2/10
$3.79 $3.32▼ −12.53%▼ −9.78%$3.15 (−16.89%)
May 6, 2026
5w ago
Press Release
MIXED ★ 6/10
$3.43 $3.15▼ −8.16%▼ −9.29%$3.15 (−8.16%)
May 5, 2026
5w ago
Insider Cluster
NEUTRAL ★ 2/10
$3.37 $3.26▼ −3.26%▼ −5.25%$3.15 (−6.53%)
Apr 7, 2026
9w ago
Insider Cluster
NEUTRAL ★ 3/10
$3.19 $3.54▲ +10.97%▲ +5.64%$3.15 (−1.25%)
Mar 25, 2026
11w ago
Press Release
NEUTRAL ★ 3/10
$3.17 $3.06▼ −3.47%▼ −3.23%$3.15 (−0.63%)
Mar 17, 2026
12w ago
Insider Cluster
NEUTRAL ★ 3/10
$3.42 $3.17▼ −7.31%▼ −4.66%$3.15 (−7.89%)
Feb 25, 2026
15w ago
8-K
BULLISH ★ 8/10
$3.77 $3.64▼ −3.45%▼ −2.35%$3.15 (−16.45%)
Showing 9 of 9

US Market Status

Market Closed — Opens Mon (46h 47m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access